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This, in combination with available package insert data,
supports a wider range of options for preparation. In
December 2011 we implemented a simpler technique for
administration of melphalan by preparing all doses in a total
volume of 250 mL NS. This method yields concentrations
between 0.45 to 2 mg/mL for patients of a BSA from 0.81 to
3.56 m2 for 140 mg/m2 doses and 0.57 to 2.5 m2 for 200 mg/
m2 doses. In a review of the ﬁrst 30 autologous HCT patients
who received melphalan 200 mg/m2 via this method, me-
dian engraftment was on days 12 and 16 for neutrophils and
platelets, respectfully, which is the same as our historical
data for this transplant regimen. To date this method has
been used for over 350 transplant patients. This practice
change simpliﬁed both pharmacy and nursing procedures
such that all doses are dispensed in a single bag with a total
volume of 250 mL and infused via one infusion pump at a
standard rate of 500 mL/hour. This simpliﬁed compounding
and administration of doses decreases time spent by both
pharmacy and nursing for treatments using melphalan. The
use of a single bag and one standard infusion rate also re-
duces the likelihood of administration errors by eliminating
the need to calculate infusion rates and coordinate the use of
multiple pumps.456
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Background: Busulfan is an alkylating agent commonly used
for myeloablation in hematopoietic stem cell transplantation
(SCT). Narrow therapeutic index and 2-3 fold interpatient PK
variability underscores the need to further explore predictors
of busulfan clearance. This analysis aimed to predict the
percentage of patients who were within the targeted AUC
range of 4800 mM*minwith dosing strategies based on actual
body weight (ABW) or adjusted body weight (AdBW, and to
determine patient characteristics that may impact busulfan
clearance.
Methods: This retrospective analysis assessed allogeneic SCT
patients who received a test dose of 0.8 mg/kg IV busulfan,
dosed by AdBW, prior to conditioning therapy containing
therapeutically dosed busulfan. All patients were treated
between June 2004 and July 2013 at the University of North
Carolina at Chapel Hill. Noncompartmental PK parameters
were calculated from this test dose using Phoenix
WinNonlinPharsight software. Measured PK data were
obtained from test the test dose and used to extrapolate an
AUC for ABWand AdBW. Acceptable AUCs werewithin 15% of
the targeted of 4800 mM*min.
A linear model with log of busulfan test dose clearance as
an outcome and patient characteristics that included disease
state, bone marrow donor type, gender, race, ethnicity, body
surface area (BSA), anticonvulsant prophylaxis used (leve-
tiracetam or phenytoin), total bilirubin and serum creatinine
was ﬁt.
Results: The study reviewed a total of 102 patients with a
mean age of 40.3 (range 18 to 63). The analysis included 63males, 87 Caucasians, and 5 African Americans. Seizure
prophylaxis with levetiracetamwas given to 41 patients, and
51 patients received phenytoin. Based extrapolated PK data,
42% of patients dosed by ABW were within targeted AUC
range, versus 47% of patients dosed by AdBW.
After adjusting for patient characteristics, a unit increase
in BSA was associated with 0.68 (p ¼ < 0.001) increase in
busulfan log(clearance). Although not statistically signiﬁcant,
African American race was associated with a trend towards
decreased clearance (p ¼ 0.064). No correlation was seen for
age (p ¼ 0.226), gender (p ¼ 0.417337), or for any other
variable that was assessed.
Discussion: Weight-based busulfan dosing using AdBW or
ABW each results in <50% of patients being achieving a goal
AUC of 4800 mM*min. Interpatient variability of IV busulfan
may be partially explained by BSA, yet differences in race,
gender, and age did not correlate busulfan clearance. These
data suggest that other dosing strategies, such as PK-guided
dosing, may help to minimize over/under dosing and to
overcome interpatient variability.457
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Background: Allogeneic hematopoietic cell transplant (HCT)
is increasingly used to treat patients with malignancies. The
use of pre-HCT immunosuppressive conditioning chemo-
therapy and post-HCT immunosuppression predispose these
patients to infections. A departmental vaccination guideline
was implemented in Singapore General Hospital (SGH) in
year 2004. As a clinical improvement initiative to facilitate
easy reference and prompt prescribing, the guideline was
updated and modiﬁed into a vaccination chart detailing the
vaccines needed at various time-points in October 2012. This
chart was ﬁled in the patients’ progress notes to ensure ac-
curate tracking of patients’ vaccination status. The aim of this
study was to review the usefulness of this chart in facilitating
prompt prescribing.
